Strong Results Boosted Guardant Health (GH) in Q2

2 months ago 42

Soumya Eswaran

Tue, July 21, 2026 astatine 9:07 AM CDT 3 min read

Fred Alger Management, an concern absorption company, released its "Alger Small Cap Focus Fund" second-quarter 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. U.S. equities experienced a beardown betterment successful Q2 2026, with the S&P 500 Index gaining 15.2%, marking its champion 4th since 2020. A ceasefire betwixt the United States and Iran and accelerated concern successful artificial quality (AI) fueled marketplace optimism successful the quarter, driving the Information Technology and Industrials sectors guardant portion Energy and Utilities lagged owed to falling lipid and state prices. In June, the Federal Reserve maintained dependable involvement rates, but the gathering had a hawkish tone. As AI transitions into its agentic phase, opportunities are identified wrong sectors adopting the technology. The Alger Small Cap Focus Fund's Class A shares outperformed the Russell 2000 Growth Index successful the quarter, driven by beardown performances successful the Industrials and Health Care sectors, portion Financials and Consumer Discretionary detracted from the performance. In addition, delight cheque the Fund's apical 5 holdings to cognize its champion picks successful 2026.

In its Q2 2026 capitalist letter, Alger Small Cap Focus Fund highlighted Guardant Health, Inc. (NASDAQ:GH). Guardant Health, Inc. (NASDAQ:GH) is simply a precision oncology institution that specializes successful a liquid biopsy trial to observe crab from humor samples. On July 20, 2026, Guardant Health, Inc. (NASDAQ:GH) closed astatine $148.07 per share. One-month instrumentality of Guardant Health, Inc. (NASDAQ:GH) was 13.18%, and its shares gained 220.15% implicit the past 52 weeks. Guardant Health, Inc. (NASDAQ:GH) has a marketplace capitalization of $19.63 billion.

Alger Small Cap Focus Fund stated the pursuing regarding Guardant Health, Inc. (NASDAQ:GH) successful its Q2 2026 capitalist update:

"Guardant Health, Inc. (NASDAQ:GH) is simply a precision oncology institution that develops blood-based liquid biopsy tests spanning therapy selection, recurrence monitoring, and aboriginal crab detection, anchored by its Guardant360, Reveal, and Shield platforms. We proceed to presumption the institution arsenic 1 of the much strategically positioned names successful molecular diagnostics, with enactment successful liquid biopsy supported by a heavy objective grounds base, an expanding acceptable of companion diagnostic labels, and a credible runway toward escaped currency travel breakeven. Shares contributed positively to show during the quarter, advancing connected first-quarter results that prompted absorption to rise full-year 2026 gross guidance, the inclusion of the Shield humor trial successful updated colorectal crab screening guidelines, and regulatory support of Guardant360 CDx arsenic a companion diagnostic for Boehringer Ingelheim's Hernexeos."

Read Entire Article